Skip to main content
Fig. 3 | Cellular & Molecular Biology Letters

Fig. 3

From: N6-methyladenosine-modified circ_104797 sustains cisplatin resistance in bladder cancer through acting as RNA sponges

Fig. 3

circ_104797 is modulated by m6A RNA methylation. A Identification of the potential m6A site in circ_104797, as determined by the convergence of results from the sequence-based N6-methyladenosine (m6A) site prediction tools SRAMP and RMBase v2.0; B MeRIP-qPCR analysis illustrating the relative enrichment of circ_104797 when immunoprecipitated with m6A antibody (m6A-IP) compared with IgG in BCa cells; C bioinformatics analysis using online platforms (https://circinteractome.nia.nih.gov/, http://rbpdb.ccbr.utoronto.ca/) suggested potential interactions between circ_104797 and specific RNA binding proteins (RBP); D RNA pulldown assays complemented by western blotting revealed interactions of circ_104797 with METTL3, ALKBH5, and IGF2BP1/2; E, F RBP immunoprecipitation (RIP) followed by qPCR analysis indicated significant enrichment of circ_104797 in the anti-ALKBH5 and anti-IGF2BP2 antibody groups compared to the IgG control in T24/CDDP (E) and 5637/CDDP (F) cells

Back to article page